.png&w=3840&q=75)
Invest in the Sky’s Operating System
Drones and air taxis will overwhelm today’s air traffic system. A $200 billion “iOS for the sky” is coming, and the firms building it will capture toll-booth profits.

Sleep assistance used to be a lifestyle fad, somewhere between yoga mats and scented candles. Now it is hard science with a hundred-billion-dollar economy attached. From wearables to prescription drugs, the market for better rest is wide awake for investments.
By Austin Payne
A new Nature magazine article about sleep makes one thing clear: While Sleep was once treated as lifestyle fluff, it is now a hundred-billion-dollar asset class with hard science at its core.
Scientists are increasingly understanding just how important sleep is for overall health and performance in every aspect of our lives. Sleep has become an important, meticulously tracked biomarker, and rightfully so. So next time you hear the term “needing your beauty sleep,” there’s data backing it.
Prescription insomnia drugs like Idorsia’s Quviviq and narcolepsy therapies from Jazz Pharma show how the sleep market has become a viable business. These are not fads, but evidence-backed products with multi-year cash flows.
The FDA has now cleared the Apple Watch for sleep-apnea detection, turning bedtime data into medical referrals powered by your pillow. That locks users into Apple’s ecosystem while funneling patients downstream to diagnostics. The sleep-apnea devices market is already valued at $8–10 billion and growing steadily, so the health-tech crossover is real.
Beyond Apple, a thriving ecosystem of tracking devices exists. Oura, Whoop, and other platforms have turned sleep into a competitive sport, selling subscriptions, data insights, and integrations with health apps. What started as a niche has become a recurring-revenue business model with millions of users paying to know how well they rest.
Stress, aging, and digital lifestyles keep eroding rest. By 2035, one in three adults is projected to face chronic sleep issues. That is a recurring demand baked into demographics. Investors usually dream of secular growth stories. This one literally comes with built-in insomnia.
Sleep has gone from a self-care fad to a regulated science. With FDA-cleared wearables, approved insomnia drugs, and reimbursable therapies, the “sleep economy” has become a medical-grade market. Here are the best ways to get in on this opportunity.
Sleep is now a regulated, data-driven industry. The convergence of wearables, prescription therapies, and digital diagnostics makes it one of the most investable health frontiers of the decade. Investors seeking predictable cash flows with multi-year patent-backed companies will find these funds suitable.
.png&w=3840&q=75)
Drones and air taxis will overwhelm today’s air traffic system. A $200 billion “iOS for the sky” is coming, and the firms building it will capture toll-booth profits.
.png&w=3840&q=75)
Zelensky swapped his fatigues for a suit in Washington, arriving with Europe’s top leaders. Behind the optics is a trillion-dollar defense spending wave. Here’s who stands to benefit.

W-2 jobs are fading, freelancing is mainstream, and cities are shaking down gig platforms for millions. Here’s your finance play on the gig economy trends.
Next article

Trump’s Executive Order is dismantling surveillance banking and opening the door to alternative sovereign finance that you can take advantage of.
By Joseph Sherman

Sign up to get our curated newsletter in your inbox.